← Back to Search

Omega-3 Fatty Acids

Omega-3 fatty acids for Metabolic Syndrome

Phase < 1
Waitlist Available
Led By Pathmaja Paramsothy, MD
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

The purpose of this study is to determine the effects of omega-3 fatty acids in the form of fish oil supplementation (approximately 2 grams per day) on the carotid intima-media (CIMT)progression (primary objective) and 2)(Secondary objective) lipid markers such as LDL, apo-B, and LDL buoyancy, on inflammatory burden as measured by CRP, on oxidative stress as measured by urinary isoprostanes, urine microalbumin/creatinine, and serum adiponectin a fat derived hormone in subjects with metabolic syndrome.

Eligible Conditions
  • Metabolic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Placebo Group
Group I: 1Placebo Group1 Intervention
Omega-3 fatty acid vs. placebo comparator

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,812 Previous Clinical Trials
1,913,687 Total Patients Enrolled
8 Trials studying Metabolic Syndrome
638 Patients Enrolled for Metabolic Syndrome
PfizerIndustry Sponsor
4,650 Previous Clinical Trials
17,743,563 Total Patients Enrolled
9 Trials studying Metabolic Syndrome
1,153 Patients Enrolled for Metabolic Syndrome
National Institutes of Health (NIH)NIH
2,810 Previous Clinical Trials
8,159,532 Total Patients Enrolled
11 Trials studying Metabolic Syndrome
2,087 Patients Enrolled for Metabolic Syndrome
~5 spots leftby Nov 2025